Dark Light
First-in-class T cell engager approved for lung cancer

Technology tamfitronics

  • News in Brief
  • Published:

Nature Biotechnology volume42,page 824 (2024)Cite this article

Amgens T cell engager Imdelltra (tarlatamab) has gained FDA accelerated approval for an aggressive type of cell lung cancer that is notoriously difficult to treat.

The bispecific antibody is designed to bind both delta-like ligand 3 (DLL3) on small cell lung cancer (SCLC) cells and CD3 on T cells. Pharma companies have long considered DDL3 a promising target in oncology because healthy cells express it only in the cytoplasm, whereas 8596% of SCLCs express it at high levels on the tumor cell surface. By binding DDL3 on the one hand and CD3 on T cells on the other, the T cell engager brings the patients own immune cells and cancer cells into physical proximity, enabling the activated T cells to attack and kill DLL3-expressing cancer cells.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 /30days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

214,86 per year

only 17,91 per issue

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

About this article

Technology tamfitronics Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First-in-class T cell engager approved for lung cancer. Nat Biotechnol 42824 (2024). https://doi.org/10.1038/s41587-024-02291-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-024-02291-3

https://www.tamfitronics.com/privacy-policy/

Discover more from Tamfitronics

Subscribe now to keep reading and get access to the full archive.

Continue reading